252 related articles for article (PubMed ID: 34504651)
1. Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.
Chen TJ; Du W; Junco JJ; Bridges CS; Shen Y; Puppi M; Rabin KR; Lacorazza HD
Oncotarget; 2021 Aug; 12(18):1787-1801. PubMed ID: 34504651
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
Shen Y; Park CS; Suppipat K; Mistretta TA; Puppi M; Horton TM; Rabin K; Gray NS; Meijerink JPP; Lacorazza HD
Leukemia; 2017 Jun; 31(6):1314-1324. PubMed ID: 27872496
[TBL] [Abstract][Full Text] [Related]
3. 5Z-7-Oxozeaenol covalently binds to MAP2K7 at Cys218 in an unprecedented manner.
Sogabe Y; Matsumoto T; Hashimoto T; Kirii Y; Sawa M; Kinoshita T
Bioorg Med Chem Lett; 2015 Feb; 25(3):593-6. PubMed ID: 25529738
[TBL] [Abstract][Full Text] [Related]
4. Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia.
Bridges CS; Chen TJ; Puppi M; Rabin KR; Lacorazza HD
Blood Adv; 2023 Feb; 7(3):422-435. PubMed ID: 36399528
[TBL] [Abstract][Full Text] [Related]
5. Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Shen Y; Chen TJ; Lacorazza HD
Exp Hematol; 2017 Sep; 53():16-25. PubMed ID: 28479419
[TBL] [Abstract][Full Text] [Related]
6. Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.
Zhang J; Li B; Wu H; Ou J; Wei R; Liu J; Cai W; Liu X; Zhao S; Yang J; Zhou L; Liu S; Liang A
Tumour Biol; 2016 Jan; 37(1):531-9. PubMed ID: 26227222
[TBL] [Abstract][Full Text] [Related]
7. Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells.
Acuña UM; Wittwer J; Ayers S; Pearce CJ; Oberlies NH; DE Blanco EJ
Anticancer Res; 2012 Jul; 32(7):2415-21. PubMed ID: 22753698
[TBL] [Abstract][Full Text] [Related]
8. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.
Wu J; Powell F; Larsen NA; Lai Z; Byth KF; Read J; Gu RF; Roth M; Toader D; Saeh JC; Chen H
ACS Chem Biol; 2013 Mar; 8(3):643-50. PubMed ID: 23272696
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
10. Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells.
Hrabe JE; O'Leary BR; Fath MA; Rodman SN; Button AM; Domann FE; Spitz DR; Mezhir JJ
Redox Biol; 2015 Aug; 5():319-327. PubMed ID: 26114584
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
[TBL] [Abstract][Full Text] [Related]
12. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
13. Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line.
Hosseini MS; Mohammadi MH; Vahabpour Roudsari R; Jafari L; Mashati P; Gharehbaghian A
Iran J Pharm Res; 2019; 18(Suppl1):132-145. PubMed ID: 32802094
[TBL] [Abstract][Full Text] [Related]
14. Effects of (5Z)-7-oxozeaenol on the oxidative pathway of cancer cells.
Acuña UM; Wittwer J; Ayers S; Pearce CJ; Oberlies NH; DE Blanco EJ
Anticancer Res; 2012 Jul; 32(7):2665-71. PubMed ID: 22753724
[TBL] [Abstract][Full Text] [Related]
15. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
16. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
18. Monoallelic
Veiga DFT; Tremblay M; Gerby B; Herblot S; Haman A; Gendron P; Lemieux S; Zúñiga-Pflücker JC; Hébert J; Cohen JP; Hoang T
Front Immunol; 2022; 13():867443. PubMed ID: 35401501
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes.
Li W; Jiang Z; Li T; Wei X; Zheng Y; Wu D; Yang L; Chen S; Xu B; Zhong M; Jiang J; Hu Y; Su H; Zhang M; Huang X; Geng S; Weng J; Du X; Liu P; Li Y; Liu H; Yao Y; Li P
Mol Cancer; 2015 Feb; 14():26. PubMed ID: 25644173
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia.
Nguyen TL; Nokin MJ; Terés S; Tomé M; Bodineau C; Galmar O; Pasquet JM; Rousseau B; van Liempd S; Falcon-Perez JM; Richard E; Muzotte E; Rezvani HR; Priault M; Bouchecareilh M; Redonnet-Vernhet I; Calvo J; Uzan B; Pflumio F; Fuentes P; Toribio ML; Khatib AM; Soubeyran P; Murdoch PDS; Durán RV
Mol Oncol; 2021 May; 15(5):1412-1431. PubMed ID: 33314742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
